Conmed Corp SEC Filings

CONMED Corp director Barbara J. Schwarzentraub reported equity compensation and a routine option-like exercise. She received 5,772 RSUs on June 1, 2026, each representing a contingent right to one share of common stock under the 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after one year. On June 2, 2026, 668 RSUs were exercised and converted into 668 shares of common stock, leaving her with 5,012 shares of common stock held directly. A separate line shows 1,442 shares of common stock held indirectly by The Barbara J. Schwarzentraub Trust.

CONMED Corporation’s interim corporate controller and principal accounting officer, Kimberly Lockwood, reported her existing equity holdings. She directly holds 1,868 shares of common stock, along with multiple grants of restricted stock units and stock options that provide potential future rights to additional common shares.

The RSUs each represent a right to receive one share of CONMED common stock, generally vesting over a three‑year period under the company’s 2025 Long-Term Incentive Plan. The stock options were granted under CONMED’s 2015 and 2018 Long-Term Incentive Plans and typically vest evenly over five years, with exercise prices ranging from $58.33 to $144.55 per share and expirations between 2028 and 2035.

CONMED Corp reported initial holdings for Kimberly Lockwood, Interim Corporate Controller and Principal Financial Officer. The Form 3 shows direct ownership of 1,868 shares of common stock and multiple equity awards granted under the company’s long-term incentive plans.

Lockwood holds RSUs covering 2,838 and 2,839 underlying shares of common stock, which generally vest over three years under the 2025 Long-Term Incentive Plan. She also holds several option grants on common stock, with exercise prices ranging from $58.33 to $144.55 per share and expiration dates between 2028 and 2035, typically vesting in equal installments over five years.

CONMED Corporation entered into a First Omnibus Amendment to its existing credit documents to add a new $450 million senior secured delayed draw Term A-2 Loan Facility. This facility is available in a single draw through June 14, 2026 and matures on June 10, 2030, matching CONMED’s existing revolving and term loans.

The company plans to use the Term A-2 proceeds to repurchase a portion of its outstanding 2.25% Convertible Senior Notes due 2026 and to pay related fees and expenses. Interest on the new loans will be based on adjusted term SOFR plus a margin of 1.125%–2.25% or a base rate plus 0.125%–1.25%, tied to CONMED’s consolidated senior secured leverage ratio, with initial margins of 1.75% for SOFR loans and 0.75% for base rate loans.

CONMED Corporation reports several governance updates. The board will expand to nine directors and has appointed Celine Martin and Jeff Mirviss as independent directors effective July 1, 2026, with committee assignments across audit, strategy, compensation, and governance. The board also named Kimberly Lockwood interim Corporate Controller and interim Principal Accounting Officer effective June 1, 2026.

Amended and restated bylaws update advance notice rules, including a 90–120 day window for 2027 annual meeting nominations and proposals, with notices due between January 18 and February 17, 2027. At the May 18, 2026 annual meeting, stockholders elected seven directors, approved the advisory vote on executive compensation, and ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026.

CONMED Corporation reported higher profitability for the quarter ended March 31, 2026, despite slightly lower sales. Net sales were $317.0 million versus $321.3 million a year earlier, mainly because gastroenterology product revenue fell to $9.5 million from $25.0 million as the company exited that portfolio.

Net income more than doubled to $13.8 million from $6.0 million, and diluted EPS rose to $0.45 from $0.19, helped by stronger gross margins and lower selling and administrative costs. Gross margin expanded to 57.9% from 55.3%, aided by a benefit from terminating the Gore VIABIL biliary stent distribution agreement and lower supply-chain consulting costs. Operating cash flow declined to $13.5 million from $41.5 million, reflecting working-capital swings and higher incentive payments. The company generated $7.0 million from selling certain gastroenterology assets, repurchased $37.0 million of stock, and ended the quarter with $35.0 million in cash and $860.9 million of total debt, including $800.0 million of 2.250% convertible notes due 2027 that it plans to refinance.

CONMED Corp reports beneficial ownership of 1,619,070 shares as of 03/31/2026. Vanguard Capital Management states it has sole dispositive power over 1,619,070 shares and sole voting power over 235,028 shares, representing 5.25% of the class. The filing names affiliated Vanguard entities that exercise dispositive or voting power on certain managed accounts.

CONMED Corporation reported first quarter 2026 net sales of $317.0 million, down 1.3% year-over-year, as the exit of certain gastroenterology products reduced sales by $15.5 million. Domestic revenue fell 5.8%, while international revenue grew 4.7% as reported.

GAAP diluted earnings per share rose to $0.45 from $0.19 a year earlier, and adjusted diluted EPS was $0.89 versus $0.95. EBITDA was $44.3 million and adjusted EBITDA was $56.4 million, compared to $61.3 million in 2025.

Management raised its 2026 outlook for organic constant currency revenue growth to 5.0%–6.5% and now expects full-year reported revenue of $1.350 billion to $1.375 billion, while reaffirming adjusted diluted EPS guidance of $4.30 to $4.45.

CONMED Corp reported that Vanguard Portfolio Management beneficially owns 2,120,886 shares of Common Stock, representing 6.87% of the class as reported in a Schedule 13G. The filing states Vanguard has sole dispositive power over 2,120,886 shares and sole voting power over 44,469 shares. The filing is signed by Ashley Grim and dated 04/29/2026.